




# A novel *in vitro* tubular model to recapitulate features of distal airways: the bronchioid

Elise Maurat, Katharina Raasch, Alexander M. Leipold, Pauline Henrot, Maeva Zysman, Renaud Prevel, Thomas Trian, Tobias Krammer, Vanessa Bergeron, Matthieu Thumerel , Pierre Nassoy, Patrick Berger , Antoine-Emmanuel Saliba, Laetitia Andrique, Gaëlle Recher and Isabelle Dupin 



**GRAPHICAL ABSTRACT** Overview of the study: the bronchioid model.



# A novel *in vitro* tubular model to recapitulate features of distal airways: the bronchioid

Elise Maurat<sup>1,2,9</sup>, Katharina Raasch<sup>1,2,9</sup>, Alexander M. Leipold<sup>3,7</sup>, Pauline Henrot<sup>1,2,4</sup>, Maeva Zysman<sup>1,2,4</sup>, Renaud Prevel<sup>1,2,4</sup>, Thomas Trian<sup>1,2</sup>, Tobias Krammer<sup>3</sup>, Vanessa Bergeron<sup>5</sup>, Matthieu Thumerel<sup>1,2,4</sup>, Pierre Nassoy<sup>6</sup>, Patrick Berger<sup>1,2,4</sup>, Antoine-Emmanuel Saliba<sup>3,7</sup>, Laetitia Andrique<sup>5</sup>, Gaëlle Recher<sup>6</sup> and Isabelle Dupin<sup>1,2,8</sup>

<sup>1</sup>Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC1401, Pessac, France. <sup>2</sup>INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC1401, Pessac, France. <sup>3</sup>Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection Research (HZI), Würzburg, Germany. <sup>4</sup>CHU de Bordeaux, Service d'exploration fonctionnelle respiratoire, Service de réanimation, Service de chirurgie thoracique, Bordeaux, France. <sup>5</sup>VoxCell Facility, TBMcore UAR CNRS 3427, INSERM US 005, Univ-Bordeaux, Bordeaux, France. <sup>6</sup>Laboratoire Photonique, Numérique et Nanosciences, UMR 5298 CNRS, Univ-Bordeaux, Bordeaux, France. <sup>7</sup>University of Würzburg, Faculty of Medicine, Institute of Molecular Infection Biology (IMIB), Würzburg, Germany. <sup>8</sup>Institut Universitaire de France (IUF), Paris, France. <sup>9</sup>Equal contribution as joint first authors.

Corresponding author: Isabelle Dupin ([isabelle.dupin@u-bordeaux.fr](mailto:isabelle.dupin@u-bordeaux.fr))



Shareable abstract (@ERSpublications)

A novel tubular engineered lung model called a “bronchioid” exhibits mucociliary function and is compatible with the establishment of an air-liquid interface <https://bit.ly/3LMdnkx>

**Cite this article as:** Maurat E, Raasch K, Leipold AM, *et al.* A novel *in vitro* tubular model to recapitulate features of distal airways: the bronchioid. *Eur Respir J* 2024; 64: 2400562 [DOI: 10.1183/13993003.00562-2024].

Copyright ©The authors 2024.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

This article has an editorial commentary: <https://doi.org/10.1183/13993003.01531-2024>

Received: 9 May 2023  
Accepted: 21 July 2024

## Abstract

**Background** Airflow limitation is the hallmark of obstructive pulmonary diseases, with the distal airways representing a major site of obstruction. Although numerous *in vitro* models of bronchi already exist, there is currently no culture system for obstructive diseases that reproduces the architecture and function of small airways. Here, we aimed to engineer a model of distal airways to overcome the limitations of current culture systems.

**Methods** We developed a so-called bronchioid model by encapsulating human bronchial adult stem cells derived from clinical samples in a tubular scaffold made of alginate gel.

**Results** This template drives the spontaneous self-organisation of epithelial cells into a tubular structure. Fine control of the level of contraction is required to establish a model of the bronchiole, which has a physiologically relevant shape and size. Three-dimensional imaging, gene expression and single-cell RNA-sequencing analysis of bronchioids made of bronchial epithelial cells revealed tubular organisation, epithelial junction formation and differentiation into ciliated and goblet cells. Ciliary beating was observed, at a decreased frequency in bronchioids made of cells from COPD patients. The bronchioid could be infected by rhinovirus. An air-liquid interface was introduced that modulated gene expression.

**Conclusion** Here, we provide a proof of concept of a perfusable bronchioid with proper mucociliary and contractile functions. The key advantages of our approach, such as the air-liquid interface, lumen accessibility, recapitulation of pathological features and possible assessment of clinically relevant end-points, will make our pulmonary organoid-like model a powerful tool for preclinical studies.

## Introduction

Chronic obstructive diseases such as COPD and asthma are major public health challenges characterised by airflow limitation. There is a lack of specific curative treatments for these diseases, in part because of the paucity of integrative approaches for deciphering their pathophysiology, especially for the distal airways. On the one hand, animal and especially rodent models are widely used for preclinical studies, but their airways differ anatomically, histologically and physiologically from those of humans, and they do not fully recapitulate disease hallmarks [1]. To date, they have poorly predicted which drugs will help treat patients with chronic obstructive diseases. On the other hand, the lung has a complex structure leading to a



peculiar stiffness and three-dimensional (3D) conformation that is difficult to model *in vitro*, highlighting the need to create adequate complex cellular models.

Various strategies have been proposed to model human bronchi *in vitro* [2]. Two-dimensional (2D) culture of bronchial epithelial cells (BECs) at the air–liquid interface (ALI) allows the reconstitution of a fully differentiated epithelium with functional cilia, with easy access to the apical and basal sides [3, 4], but it does not reproduce the 3D architecture essential for properly modelling the airways. 3D bioprinting is a promising method for building tissue with a relevant geometry [5, 6], especially with the recent development of suitable bioinks, such as those composed of alginate and decellularised tissue, enabling the printing of a tubular structure [7]. However, the length of the tubes obtained is limited, and 3D printing of the last branches of the bronchial tree remains below the resolution limit of current bioprinting techniques. The elegant microfluidic approach has been used to design so-called airway-on-a-chip [8, 9], providing unique advantages such as the ability to perfuse air, particles or nebulised drugs; to incorporate immune cells; and the potential application of cyclic stretching to reproduce breathing movements. While the microengineered scaffold restricts morphogenesis to a predefined geometry, it does not completely match the exact topology of a bronchus and does not offer a permissive and remodelable environment.

Other studies, starting from BENALI *et al.* [10] to more recent ones [11–13], have favoured the third dimension with “bronchospheres”, in which BECs are embedded in a gel and self-organise into spheres with a liquid-filled lumen [14]. These self-renewing organoids exhibit ciliary activity and mucus production. In most of the bronchospheres, the apical side of the cells faces the inside of the organoid, limiting access to the lumen, although protocols to reverse airway organoid polarity have been developed [15, 16]. This closed and spherical architecture also impairs the removal of apical side-released dead cells inside and the introduction of an ALI. Finally, the formation of invasive tubular structures from lung organoids has been observed [17], but this process remains stochastic and rather limited.

Cellular Capsule Technology, adapted from a co-extrusion microfluidic technique, has been used to encapsulate cells and extracellular matrix proteins in a tubular scaffold made of alginate gel [18]. Cell-laden microfibrils have been generated with various cell types, such as endothelial cells, epithelial cells, fibroblasts, skeletal muscle cells and nerve cells [18]. When co-encapsulated, endothelial and vascular smooth muscle cells self-organise into tubular structures that model vessels [19]. Although epithelial cell lines such as the human hepatoma G2 (HepG2) cell line, the mouse pancreatic  $\beta$ -cell (MIN6m9) cell line, the cervical cancer Henrietta Lacks (HeLa) cell line, the Madin-Darby Canine Kidney (MDCK) cell line and the EpH4-J3B1A mammary gland epithelial cell line have been previously successfully used [18, 20], the behaviour of primary BECs in this culture system has never been investigated.

Here, we aimed to construct a tubular organoid-like model of distal airways with human primary BECs. By using a tubular template made of alginate using Cellular Capsule Technology, we were able to drive the spontaneous self-organisation of lung epithelial cells to obtain a 3D “bronchioid” model with a physiologically relevant shape and size. Importantly, the tubular geometry allows lumen access to create an ALI.

## Methods

### Patients

Macroscopically normal lung resection material for the purification of basal epithelial cells was obtained from a cohort of patients requiring thoracic lobectomy surgery for nodules or cancer (pN0) (*i.e.* TUBE, sponsored by the University Hospital of Bordeaux, which includes its own local ethics committee (CHUBX 2020/54)). As per French law and MR004 regulations, patients received an information form, allowing them to refuse the use of their surgical samples for research. The research was conducted according to the principles of the World Medical Association Declaration of Helsinki. A total of 11 COPD patients with a clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines [21] and 18 non-COPD patients with normal lung function (*i.e.* forced expiratory volume in 1 s (FEV<sub>1</sub>) to forced vital capacity (FVC) ratio >0.70) were enrolled from the University Hospital of Bordeaux (table 1). Five other patients were also enrolled from the TUBE cohort for the comparison of bronchioids to classical ALI culture (supplementary table E1). All clinical data were collected at the Clinical Investigation Center (CIC1401) of the University Hospital of Bordeaux.

### Bronchial epithelial cell culture

Human basal BECs were derived from bronchial specimens as described previously [22]. Bronchial epithelial tissue was cultured in PneumaCult-Ex medium (STEMCELL Technologies, Vancouver, Canada) under a water-saturated 5% CO<sub>2</sub> atmosphere at 37°C until basal BECs reached 80–90% confluence. For ALI culture, basal BECs were plated (1.10<sup>5</sup> cells per well) on tissue culture-treated nucleopore membranes

**TABLE 1** Patient characteristics for bronchioid generation

	Non-COPD patients	COPD patients	p-value
<b>Subjects (n)</b>	18	11	
<b>Age (years)</b>	67.3±8.6	67.0±5.2	0.92
<b>Sex</b>			>0.99
Male	8	5	
Female	10	6	
<b>Smoking history</b>			0.64
Current	5	2	
Former	10	8	
Nonsmoker	3	1	
<b>Pack years</b>	26.7±17.8	42.7±33.6	0.22
<b>PFT</b>			
FEV <sub>1</sub> (% predicted)	90.9±29.6 <sup>#</sup>	73.2±22.8 <sup>#</sup>	0.08
FEV <sub>1</sub> /FVC ratio (%)	75.7±10.5 <sup>#</sup>	61.8±13.8 <sup>#</sup>	<0.0001

Data are presented as mean±SD, unless otherwise indicated. p-values were calculated using Fisher's exact test for comparison of proportions and the Mann-Whitney test for comparison of nonparametric variables. PFT: pulmonary function test; FEV<sub>1</sub>: forced expiratory volume in 1 s; FVC: forced vital capacity. #: one missing value; #: two missing values (where FEV<sub>1</sub>/FVC was not available, COPD had been previously diagnosed by a physician).

(ref 3470, 6.5 mm diameter, 0.4 µm pore size; Transwell, Costar) in PneumaCult-ALI Medium (STEMCELL Technologies) applied at the basal side only to establish the ALI. The cells were maintained in culture for 9 or 21 days.

#### *Microfluidic co-extrusion device and bronchioid formation*


The design of a co-extrusion microfluidic device for bronchioid formation has been previously described for vessels [19]. Using this device with a 450 µm-diameter nozzle, we produced hollow alginate tubes filled with basal BECs. Cells were harvested using 0.05% trypsin-EDTA (Fisher Scientific, Illkirch, France) and resuspended in Matrigel (Corning, NY, USA) and DMEM (Sigma-Aldrich, Saint Quentin-Fallavier, France), both of which ranged from 33.5% to 35% (v/v). The cell loading of the core cell suspension (CCS) varied from 30% to 33% (v/v). Cells were then injected into the central zone isolated from a 2% (w/v) alginate solution (I3G80, Alliance Gums & Industries, Ile de France, France) by a 300 mM intermediate D-sorbitol solution (Sigma-Aldrich). The experiments were performed using the following injection flow rates: 2 mL·h<sup>-1</sup> (alginate solution), 1 mL·h<sup>-1</sup> (intermediate D-sorbitol solution) and 1 mL·h<sup>-1</sup> (CCS). With these flow rates, the thickness of the alginate walls was ~50 µm, resulting in a 350 µm-diameter cell tube (figure 1a). A 100 mM calcium bath at 37°C was used to trigger rapid gelation of the alginate gel while avoiding osmotic shock. Immediately after formation (within <10 min), the cell-laden tubes were transferred to Pneumacult Airway Organoid Seeding Medium (STEMCELL Technologies) at 37°C. After 24 h, the bronchioids were transferred to Pneumacult Airway Organoid Differentiation Medium (STEMCELL Technologies) to initiate differentiation. To inhibit Rho-associated protein kinase (ROCK), the airway organoid medium was supplemented with Y-27632 (Sigma-Aldrich) at a concentration of 10 µM. The media were changed daily.

#### *Western blot*

The bronchioids were assayed for myosin light chain (MLC) II and double-phospho-MLC (PP-MLC) (Thr18, Ser19) levels by Western blotting. Total protein extracts were obtained by transferring the bronchioids to Dulbecco's PBS (DPBS) (Sigma-Aldrich) for 30 min at 37°C with gentle agitation to dissolve the alginate. After centrifugation, the pellet was suspended in RIPA lysis buffer (Santa Cruz Biotechnology, Dallas, TX, USA) supplemented with protease inhibitor cocktail and calyculin A (Sigma-Aldrich). These extracts were loaded onto a 4–20% SDS-PAGE gel (Bio-Rad, Hercules, CA, USA), transferred onto a nitrocellulose membrane and identified with a rabbit anti-target antibody (supplementary table E2). Horseradish peroxidase-coupled anti-rabbit secondary antibody was used for visualisation using a ChemiDoc imaging instrument (Bio-Rad). Protein expression was normalised to total protein loading (Stain-Free system, Bio-Rad).

#### *Quantitative real-time PCR*

Total RNA was extracted from bronchioids using a RNeasy Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). 500 ng of RNA were reverse-transcribed using the iScript Reverse



**FIGURE 1** The formation of an alginate tube filled with primary basal epithelial cells is called a “bronchioid”. **a)** Schematic of the device used to generate bronchioids. Created with BioRender.com. The three solutions were injected simultaneously by a computer-controlled pump inside a three-dimensional-printed device soaked in a 100 mM calcium bath. **b)** Left panel: brightfield images of bronchioids over time, with (+) or without (–) 10  $\mu$ M Y-27632 (Y). The green and pink dotted lines indicate the external (alginate tube) and internal (epithelial tube) limits, respectively. Scale bars: 100  $\mu$ m. Right panel: quantification of external and internal diameters (at least 10 measurements along the same tube for each condition, n=3 experiments). The medians are represented as horizontal lines. **c)** Immunoblots and analysis of myosin light chain (MLC) II and double-phospho-MLC (PP-MLC) (Thr18, Ser19) expression on day 2 in bronchioid tissue from three different donors (n=3). Total protein was used as a loading control. **d)** Upper panels: brightfield images of bronchioids cultured with 10  $\mu$ M Y-27632. Scale bars: 100  $\mu$ m. Lower panels: dot plots showing propidium iodide fluorescence (y-axis) versus annexin V-allophycocyanin fluorescence (x-axis) in cells dissociated from bronchioids and analysed by flow cytometry at the indicated time points. The percentages of propidium iodide<sup>–</sup> annexin V<sup>–</sup> cells are shown in pink. IS: intermediate D-sorbitol solution; AS: alginate solution.

Transcription Supermix (Bio-Rad). Complementary DNA (cDNA) samples were then analysed by quantitative PCR (qPCR) using Perfecta SYBR Green SuperMix (Quantabio, Beverly, MA, USA) through the CFX Connect Real-Time PCR Detection System (Bio-Rad). Primers (peptidylprolyl isomerase A (*PPIA*), forward 5'-CGGGTCCTGGCATCTTGT-3' and reverse 5'-CAGTCTTGGCAGTGCAGATGA-3'; ribosomal protein L13 (*RPL13*), forward 5'-GGGAGCAAGGAAAGGGTCTTA-3' and reverse 5'-CACCTGGACAATTCTCCGAGT-3'; glucuronidase  $\beta$  (*GusB*), forward 5'-CCATCTGGGTCTGGATCAAAA-3' and reverse 5'-TGAAATCGGCAAAATTCCAAAT-3'; keratin 5 (*KRT5*), forward 5'-GCATCACCGTTCC TGGGTAA-3' and reverse 5'-GACACACTTGACTGGCGAGA-3'; tumour protein 63 (*TP63*), forward 5'-CCTCAGGGAGCTGTTATCCG-3' and reverse 5'-ATACTGGGCATGGCTGTTCC-3'; secretoglobulin family 1A member 1 (*SCGB1A1*), forward 5'-TCCTCCACCATGAAACTCGC-3' and reverse 5'-AGGAGGGTTTCGATGACACG-3'; dynein axonemal heavy chain 5 (*DNAH5*), forward 5'-AGAGGCCATTCGCA AACGTA-3' and reverse 5'-CCCAGAAAATGGGCAAATG-3'; anterior gradient 2 (*AGR2*), forward 5'-AAGGCAGGTGGGTGAGGAAATC-3' and reverse 5'-GTCGAGAGTCCTTTGTGTCCTT-3'; mucin 5AC (*MUC5AC*), forward 5'-TACTCCACAGACTGCACCAACTG-3' and reverse 5'-CGTGTATTGCTTCCGTC-3'; epithelial cell adhesion molecule (*EPCAM*), forward 5'-CCATGTGCTGGTGTGTGAAC-3' and reverse 5'-AACGCGTTGTGATCTCCTTCT-3'; and cadherin 1 (*CDH1*), forward 5'-TTACTGCCCC AGAGGATGA-3' and reverse 5'-TGCAACGTCGTTACGAGTCA-3') were purchased from Sigma-Aldrich. mRNA expression was determined using the comparative 2- $\Delta\Delta$ Ct method and normalised to the mRNA expression level of endogenous references (*PPIA*, *RPL13* and *GusB*).

#### Generation of rhinovirus type 16-green fluorescent protein

The cDNA pA16-GFP plasmid encoding rhinovirus type 16 (RV16)-green fluorescent protein (GFP), which contains the rhinovirus sequence downstream of the T7 promoter, was a kind gift from Yury A. Bochkov (University of Wisconsin, Madison, WI, USA) [23, 24]. The reverse genetics technique developed by LEE *et al.* [24] was used to produce functional RV16-GFP virions. Briefly, for initial

production, the pA16-GFP plasmid was linearised by incubation with the restriction enzyme *Ec1136II* (EcoICRI, Thermo Scientific) at  $10 \text{ U} \cdot \mu\text{L}^{-1}$ . After purification using the QIAprep Spin Miniprep Kit (Qiagen), the DNA was transcribed *in vitro* into RNA by T7 polymerase and then transfected into HeLa cells using Lipofectamine (Invitrogen, Fisher Scientific). Finally, 24 h after transfection, the virus produced was purified and titrated by digital PCR after extraction and retrotranscription (Transcriptomic Platform, University of Bordeaux).

#### **Infection with RV16-GFP**

At days 4 to 5, an ~5 cm-long bronchioid was transferred into a 32 mm-diameter DMEM-containing Petri dish. The bronchioid was cannulated by a 30 G needle (Microlance, BD Biosciences, Eysins, Switzerland) with a diameter of 300  $\mu\text{m}$ , which is the order of magnitude of the inner diameter of the bronchioid. The needle was then connected to a 200  $\mu\text{L}$  syringe containing DMEM (Fisher Scientific) with RV16-GFP at a concentration of  $10\,000 \text{ particles} \cdot \mu\text{L}^{-1}$  and supplemented with 0.1% eosin (Clinisciences, Nanterre, France). The solution was manually injected into the bronchioid lumen, with visual control *via* an eosin stain. The cultures were not washed after infection, but the opposite side of the bronchioid was “open”, so viral particles diffused out from the lumen into the medium. At 48 h post-infection, the supernatants were collected and frozen at  $-80^\circ\text{C}$  for cytokine concentration measurements. The bronchioids were dissociated, and the cells were manually counted before being processed for fluorescence-activated cell sorting (FACS) analysis. The volume of injection corresponds to the volume of the lumen, which was estimated to be between 1  $\mu\text{L}$  and 3  $\mu\text{L}$  for 5 cm-long bronchioids containing between 12 000 and 40 000 cells, with measured lumen diameters of ~200  $\mu\text{m}$ . This allowed us to calculate a multiplicity of infection (MOI) between 0.5 and 1.5.

#### **Cytokine production**

The interferon- $\beta$  (IFN- $\beta$ ), interferon- $\lambda 1/3$  (IFN- $\lambda 1/3$ ) and C-X-C motif chemokine ligand 8 (CXCL8) concentrations in the bronchioid medium were assayed 48 h post-infection by ELISA following the manufacturer's recommendations (Bio-Techne, Minneapolis, MN, USA). Values below the detection limit were considered zero.

#### **Flow cytometry**

Epithelial cells in ALI culture were washed in PBS containing 0.5% bovine serum albumin (BSA) (Sigma-Aldrich) and 2 mM EDTA (Invitrogen, Fisher Scientific) for 4 min at  $37^\circ\text{C}$  and harvested by incubation with 0.05% trypsin-200  $\text{mg} \cdot \text{L}^{-1}$  EDTA solution (Sigma-Aldrich) for 5 min, followed by the addition of trypsin-neutralising solution (Lonza, Basel, Switzerland), as described previously [25]. For bronchioids, alginate dissolution was achieved by incubating the epithelial cell-laden tubes in DPBS for 20 min under gentle agitation. The cells were then mechanically and enzymatically dissociated by pipetting and by incubating the suspension with 0.05% trypsin-200  $\text{mg} \cdot \text{L}^{-1}$  EDTA (Sigma-Aldrich) for 5 min. After centrifugation, the cell suspension was filtered through a 70  $\mu\text{m}$  cell strainer (Corning) and immediately evaluated by flow cytometry to test for rhinovirus infection. Alternatively, annexin V-propidium iodide (Fisher Scientific) or DAPI (5  $\mu\text{g} \cdot \text{mL}^{-1}$ , Sigma-Aldrich) was used for the detection of apoptotic and dead cells, respectively, according to the manufacturer's instructions. For differentiation, cells were stained with anti-EpCAM/peridinin chlorophyll protein complex/cyanine5.5 or its isotype control (supplementary table E2), fixed, and permeabilised using the Foxp3 buffer set (Fisher Scientific) or the IntraPrep Permeabilization Reagent Kit (Beckman Coulter, Villepinte, France). The cell pellet was then stained with anti-pan cytokeratin-fluorescein isothiocyanate (FITC), anti-cytokeratin 5-Alexa Fluor 488, anti-SCGB1A1-FITC, anti-acetylated-tubulin-phycoerythrin, anti-MUC5AC-Alexa Fluor 647 or their respective isotype controls (supplementary table E2) for 1 h. FACS data were acquired using a Canto II 4-Blue 2-Violet 2-Red laser configuration (BD Biosciences). Flow cytometry analysis was performed using Diva 8 (BD Biosciences).

#### **Immunostaining**

The bronchioids were fixed with 4% paraformaldehyde (Sigma-Aldrich) diluted in DPBS supplemented with calcium (Sigma-Aldrich) for 30 min at room temperature and immunostained as described previously [26]. Briefly, after fixation, permeabilisation and blocking steps were successively performed by incubating the bronchioids with cold DPBS supplemented with calcium containing 0.1% (v/v) Tween (P1379, Sigma-Aldrich) and with cold organoid washing buffer (OWB) composed of PBS containing 2  $\text{g} \cdot \text{L}^{-1}$  BSA and 0.1% (v/v) Triton X-100 (Biosolve, Dieuze, France) at  $4^\circ\text{C}$  for 15 min. The bronchioids were then incubated with primary antibodies diluted in OWB at  $4^\circ\text{C}$  overnight with mild rocking (supplementary table E2). The bronchioids were washed three times with OWB for 2 h each and then stained with secondary antibodies, DAPI and phalloidin diluted in OWB at  $4^\circ\text{C}$  overnight, with mild rocking (supplementary table E2), before three supplementary washes with OWB for 2 h each. Next, the

bronchioids were transferred to a  $\mu$ -Slide 4-Well chamber slide (Ibidi, Gräfelfing, Germany) and resuspended in a fructose–glycerol clearing solution composed of 60% (v/v) glycerol and 2.5 M fructose in distilled H<sub>2</sub>O or in DPBS supplemented with calcium.

### Imaging

Fixed bronchioids were imaged using a confocal Leica SP8 WLL2 microscope on an inverted DMI6000 stand (Leica Microsystems, Mannheim, Germany) using a  $\times 20$  multi-immersion objective (0.75 numerical aperture HC Plan Apo CS2). White light laser 2 (WLL2) was used for the excitation of Alexa Fluor 647, 568 and 488 in the ranges of 650–750 nm, 590–640 nm and 500–550 nm, respectively. The confocal microscope was also equipped with a diode laser at 405 nm. A range of 410–480 nm was used to excite DAPI. The scanning was performed using a conventional scanner (400 Hz). The image size was 1024 $\times$ 1024 pixels, with a pixel size of 0.568  $\mu$ m and a voxel depth of 1.040  $\mu$ m. Detection was achieved with two internal photomultiplier tubes and two internal hybrid detectors. Fluorescence images were acquired with LAS X software (Leica Microsystems). Using Fiji software, the background value was subtracted from the original image, and the image contrast in the background-corrected image was adjusted. The images were then processed with Imaris software (version 9; Oxford Instruments, Abingdon, UK) for segmentation and 3D visualisation. The “clipping plane” function was used to truncate the image along a given plane in 3D space.

Live imaging to analyse ciliary beat frequency (CBF) was performed on an inverted Leica DMi8 microscope (Leica Microsystems) equipped with a Flash 4.0 sCMOS camera (Hamamatsu Photonics, Hamamatsu, Japan). The illumination system used was a Cool LED PE-4000 (CoolLED, Andover, MA, USA). The objective used was a HCX PL Fluotar L  $\times 40$  dry 0.6 numerical aperture PH2. A 37°C/5% CO<sub>2</sub> atmosphere was created with an incubator box and a gas heating system (Pecan GmbH, Erbach, Germany). Brightfield images were acquired with MetaMorph software (Molecular Devices, Sunnyvale, CA, USA) for 2 s at a frame rate of 1000 images $\cdot$ s<sup>-1</sup> in 9–10 different fields of the bronchioid region. The image size was 512 $\times$ 32 pixels, with a pixel size of 0.1625  $\mu$ m. The number of images used for the analysis was 1024. This resulted in a temporal resolution of 0.97 Hz (1000 images $\cdot$ s<sup>-1</sup> divided by 1024 images). If needed, recursive alignment of the stack of images was performed using the plugin “StackReg” of the Fiji software. Regions of interest were selected on the image generated by a maximum intensity projection using the plugin Stardist 2D of Fiji software (supplementary figure E6a). The mean grey intensity was measured in each of these regions over time, and fast Fourier transformation analysis was applied using Microsoft Excel to retrieve the different frequencies. These frequencies exhibit a discrete pattern, with an interval of 0.97 Hz between each of the possible values (supplementary figure E6b). The main frequency was taken as the CBF (supplementary figure E6b). Next, in each field, the median CBF was determined from the CBF values of the regions of interest (supplementary figure E6c). Nine to ten fields were evaluated per donor.

### Perfusion

A 3–4 cm-long bronchioid was cannulated with a 30 G needle (Microlance, BD Biosciences) with a diameter of 300  $\mu$ m. The needle was then connected to a microfluidic system (Fluigent, Le Kremlin-Bicêtre, France) composed of a microfluidic low-pressure generator (FLPG Plus), a microfluidic vacuum pressure-based controller (LineUp Push-Pull), a noninvasive flow sensor for liquid or air perfusion and a reservoir with a pressurisation cap. Air was injected into the lumen at one opened end of the bronchioid at a continuous flow rate of 0.2 mL $\cdot$ min<sup>-1</sup>. Air was released in the medium from the opposite tube end, generating visible air bubbles. Imaging was performed using an Olympus CKX53 microscope with an Olympus DP23 camera with objectives of  $\times 10$  or  $\times 20$ . Perfusion by air was continued for 4 h. After the infusion was stopped, calcein (Invitrogen) was added to the culture medium at a final concentration of 1  $\mu$ M, and the cells were incubated for 15 min at 37°C.

### Single-cell RNA-sequencing data acquisition and analysis

A single-cell suspension was obtained from bronchioids at day 21 as described for flow cytometry analysis. Cell number and viability were determined by a Trypan blue exclusion assay before proceeding with the 10x Genomics (Pleasanton, CA, USA) protocol for 3' transcript capture and single-cell library preparation. Approximately 18 000 cells were loaded on a 10x Chromium Next GEM Chip G. GEM generation, reverse transcription (RT), cleanup, cDNA amplification, fragmentation, end repair and A-tail preparation, and sample index tagging were performed using the Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead Kit v3.1 as per the manufacturer's instructions.

Quantification of the libraries was performed using a Qubit<sup>TM</sup> 2.0 Fluorometer (Thermo Fisher), and the quality of the libraries was checked with a 2100 Bioanalyzer with a high-sensitivity DNA kit (Agilent Technologies, Les Ulis, France). Libraries were sequenced using a P3 flow cell on a NextSeq2000 in

100 bp paired-end mode (Illumina, Évry, France) to read depths of 111 543 mean reads·cell<sup>-1</sup> (Patient 1) and 103 719 mean reads·cell<sup>-1</sup> (Patient 2).

The raw sequencing data were aligned to the GRCh38 human genome assembly (Ensembl98), and the transcripts were quantified using the Cell Ranger software suite (v7.1.0; 10x Genomics). Subsequently, the count matrices were loaded into R (v4.2.3; www.r-project.org), and downstream analyses were conducted using the Seurat R package (v5.0.1, [27]). Cells were filtered based on mitochondrial gene counts (<10%) and the number of genes detected per cell (>2000). Gene counts were log-normalised (NormalizeData, default parameters), and highly variable genes (HVGs) were selected (FindVariableFeatures, default parameters). Batch correction was applied using the Seurat reciprocal principal component analysis (RPCA) workflow with “Patient” as a covariate. A nearest neighbour graph was constructed (FindNeighbors, dims=1:10), and a 2D embedding was computed with the uniform manifold approximation and projection (UMAP) algorithm (RunUMAP, dims=1:10). Unsupervised clustering was performed using the Louvain algorithm (FindClusters, resolution=0.5). Cell types were annotated based on the expression of known marker genes. Ionocytes and hillock-like cells did not cluster separately in the unsupervised clustering due to their small cell number and were selected based on UMAP coordinates, because they exhibited clearly distinct locations on the UMAP representation. Differential gene expression analysis was performed using the Wilcoxon rank-sum test implemented in the Seurat package (FindAllMarkers, only.pos=TRUE, min.pct=0.25), and the differential gene expression results can be found in supplementary table E3. Additionally, cell types were predicted with the CellTypist [28] Python package (v2.1.0) using Human\_Lung\_atlas.pkl as a model, with majority voting enabled. CellTypist-predicted annotations were grouped into broader categories (e.g. “Basal resting” and “Suprabasal” were categorised as “Basal”) to facilitate comparability with the manual annotations. The adjusted Rand index was computed to assess concordance between manual annotations and CellTypist predictions.

#### *Primary lung tissue reference construction*

Primary lung tissue single-cell RNA-sequencing (scRNA-seq) data along with associated cell type annotations, clinical metadata and technical metadata were obtained from the full Human Lung Cell Atlas (HLCA) as disclosed in March 2024 [29]. Cells annotated as airway epithelium were extracted from the dataset. To ensure the technical coherence of the primary tissue reference with the bronchioid data produced in the present study, only cells analysed with 10x Genomics 3' v2 or v3 assays and derived from fresh tissue were retained for reference construction. Gene counts were log-normalised, and 3000 HVGs were selected and scaled for subsequent data integration using the Seurat RPCA workflow with “dataset” as a covariate. A nearest neighbour graph was constructed, and a 2D UMAP embedding was computed based on 30 RPCA dimensions.

#### *Neighbourhood correlation analysis*

Neighbourhood graph correlation-based similarity analysis [30] was employed to compare cell states in the bronchioid model to those in primary lung tissue from distinct anatomical locations based on the common coordinate framework (CCF) established in the HLCA [31]. Cells from the primary lung tissue reference (constructed as described above) were categorised into four CCF categories: CCF 0, corresponding to the inferior turbinate; CCF 0.36–0.5, corresponding to the trachea and the main bronchi; CCF 0.72–0.81, corresponding to lobular bronchi and distal lobular airways; and CCF 0.97, corresponding to the parenchyma [31]. For the bronchioid data as well as the primary lung tissue reference CCF categories, independent neighbourhood graphs based on transcriptional similarity were constructed with the miloR package (v1.6.0) using k=30 nearest neighbours and 30 RPCA dimensions of the respective data source [32]. The R package scrabtr (v0.1.0) was used to calculate the mean expression profiles within each neighbourhood and to compute the Pearson correlations of expression of the 3000 HVGs from the primary lung tissue reference, excluding mitochondrial genes, between all pairs of bronchioid and CCF category neighbourhoods. The maximum correlation between each bronchioid neighbourhood and a neighbourhood in the CCF-stratified primary tissue reference was considered a measure of similarity.

#### *Data and code availability*

The scRNA-seq data generated in the current study are available from Zenodo under record number 10.5281/zenodo.10834205. The R code used for scRNA-seq data analysis has been deposited on GitHub: [https://github.com/saliba-lab/Bronchioid\\_scRNAseq](https://github.com/saliba-lab/Bronchioid_scRNAseq).

## **Results**


### *Formation of the tubular bronchial epithelial model from patient-derived basal cells*

Basal BEC cultures were obtained from 29 patients (table 1, n=18 non-COPD patients, n=11 COPD patients). Using Cellular Capsule Technology, we encapsulated BECs in the presence of Matrigel into

tubular structures made of alginate (figure 1a). Notably, cells were injected at a concentration sufficient to allow immediate coverage of the entire alginate wall as soon as the tube was generated. Of the 29 samples, only one culture from a non-COPD patient (3%) failed to generate bronchioids due to a technical problem (supplementary figure E1). Nine bronchioids (n=4 non-COPD patients, n=5 COPD patients) were fully used before 9 days for early characterisation (supplementary figure E1). Among the 19 bronchioids maintained for at least 11 days in culture, 6 (32%) were from patients with COPD, which is a similar proportion to the enrolled patient population. Taken together, these findings show that bronchioids are generated with a high success rate and that they can be cultured for several weeks in a similar way whether derived from COPD or non-COPD patients.

Within the first 24 h, epithelial cells formed a monolayer that covered the entire inner part of the tube (figure 1b). However, as previously shown with epithelial cell lines [20], the bronchioid collapsed 1–2 days after encapsulation (figure 1b). Inhibition of actomyosin contractility using the ROCK inhibitor Y-27632 (10  $\mu$ M) prevented epithelial detachment (figure 1b) while decreasing the level of PP-MLC (Thr18, Ser19) (figure 1c), suggesting that cell contractility was the main driving force for shrinkage.

The dissolution of the alginate gel was successfully achieved by calcium and magnesium cation depletion for 30 min, allowing the generation of a cell suspension. Analysis of this suspension by flow cytometry demonstrated that the tubular structures remained stable and viable for at least 9 days (figure 1d). Thus, in subsequent experiments, bronchioids were continuously treated with Y27632 to avoid collapse. We confirmed the epithelial nature of the cells by flow cytometry and showed that at day 1 the cells were almost all positive for EpCAM and cytokeratin, similar to differentiated BECs at the ALI (supplementary table E1, figure 2a). The mRNA levels of *CDH1* (encoding E-cadherin) and *EPCAM*, which were measured by quantitative RT-PCR (RT-qPCR), remained stable over time (figure 2b). Confocal imaging and 3D reconstruction demonstrated the organisation of bronchial cells into a tubular structure with a typical epithelial morphology and a visible lumen, reminiscent of the structure of distal bronchi (figure 2c).



**FIGURE 2** Characterisation of the epithelial nature of cells in the bronchioid model. **a)** Dot plots representing epithelial cell adhesion molecule (EpCAM)-peridinin chlorophyll protein complex (PerCP)-cyanine 5.5 fluorescence (y-axis) versus pan cytokeratin-fluorescein isothiocyanate fluorescence (x-axis) of cells dissociated from two-dimensional (2D) air-liquid interface (ALI) culture and bronchioids at day (D) 1. The gating strategy is shown in the left panels. The percentages of EpCAM<sup>+</sup> cytokeratin<sup>+</sup> cells are shown in pink. **b)** Expression of the genes *CDH1* and *EPCAM* in bronchioids over time and in cells dissociated from 2D culture at day 9 after ALI introduction. The bronchioid and ALI culture samples were obtained from six and three different donors, respectively, and data are presented as mean $\pm$ SD. Gene expression was normalised to that of the housekeeping genes *PPIA*, *RPL13* and *GusB* and expressed relative to that of basal epithelial cells in 2D submerged culture. **c, d)** Longitudinal and transverse sections and three-dimensional (3D) views of 3D reconstructions obtained from Z-stack confocal images of a 2-day-old bronchioid stained for F-actin (phalloidin, magenta) and nuclei (DAPI, white) (**c**) and F-actin (magenta), zonula occludens-1 (ZO-1) (cyan) and nuclei (white) (**d**). Scale bars: 100  $\mu$ m and 50  $\mu$ m in the magnified lower panel.

The presence of zonula occludens-1 (ZO-1) and actin fibres at cell–cell contacts confirmed the presence of tight junctions (figure 2d).

#### **Cell differentiation and organisation in the bronchioid model**


RT-qPCR also revealed that the expression of the airway basal cell gene *KRT5* remained stable, and that of *TP63* progressively declined over time, whereas the expression of the club cell secretory marker *SCGB1A1* was highly upregulated (figure 3a). The expression of the ciliated cell markers forkhead box J1 (*FOXJ1*) and *DNAH5*, the transcription factor *AGR2* and the goblet cell marker *MUC5AC* progressively increased in culture (figure 3a). At day 9, the expression of these genes was comparable with BECs at the ALI for the same time, with the exception of *EPCAM*, *SCGB1A1* and *MUC5AC*, whose expression was greater, and *AGR2*, whose expression was reduced under the ALI condition (figures 2b and 3a). The cellular composition and viability were very similar in three different portions sampled along the tube (supplementary figure E2), indicating a homogenous cellular structure throughout the bronchioid. Using confocal microscopy, we found that ciliated cells were located in the internal layer lining the bronchioid lumen at day 11 (figure 3b and supplementary video E1). Most goblet cells also faced the lumen, with some *MUC5AC*<sup>+</sup> cells more externally localised (figure 3b). Positive staining for *MUC5AC* was also found inside the lumen, suggesting mucus secretion. Although all intermediate states of differentiation are probably not detected by simple staining, especially during the last 2 weeks in culture, flow cytometry confirmed the progressive loss of basal cells over time, with a concomitant increase in club, goblet and ciliated cells in non-COPD-derived bronchioids until day 21 (figure 3c, d). In comparison, COPD-derived bronchioids were characterised by a prominent mucous phenotype, with an already high proportion of goblet cells at day 9 (supplementary figure E3a, b). This phenotype persisted until day 21, at the expense of ciliated cells, whose percentage remained low. This resulted at day 21 in a five-fold increase in the percentage of goblet cells and an eight-fold decrease in the percentage of ciliated cells in COPD bronchioids compared with non-COPD ones (supplementary figure E3c).

#### **Single-cell characterisation of non-COPD bronchioids**

To further characterise the bronchioid model, scRNA-seq was conducted on bronchioids from two non-COPD patients after 21 days of culture (Methods). In total, 5087 high-quality single cells (Patient 1=2860 cells, Patient 2=2227 cells) were analysed (Methods and supplementary figure E4a) and categorised into nine distinct populations without noticeable differences between the donors (figure 4a and supplementary figure E4b). These populations could be annotated based on established markers, such as basal (*KRT5*, *TP63*), secretory (*SCGB1A1*, *SCGB3A1*, *MUC5B*), goblet (*MUC5AC*, *CEACAM5*), deuterosomal (*FOXN4*, *CDC20B*), ciliated (*FOXJ1*, *TTPP3*), ionocyte (*FOXI1*, *CFTR*) and hillock-like (*KRT13*, *KRT14*) cells (figure 4a, b and supplementary table E3). Additionally, populations of differentiating basal cells (*KRT5* and *AGR2*) and proliferating cells (*MKI67*) were identified. To validate the manual cell type annotations, CellTypist [28] with the HLCA [31] model were used for cell type prediction and demonstrated a high level of agreement (adjusted Rand index=0.691, supplementary figure E4c). Notably, all cell types, except for hillock-like cells (14 cells, 0.24%), were consistently observed in bronchioids derived from both patients, even if the proportions were not strictly identical (figures 4c and figure E4b). Although differentiated secretory and multiciliated lineage cells, as well as rare ionocytes and hillock-like cells, were revealed in our bronchioid scRNA-seq data, a distinct population of *SCGB3A2*<sup>+</sup> *SFTPB*<sup>+</sup> terminal airway-enriched secretory cells [33, 34] was not identified as a cluster despite the co-expression of marker genes in a few cells (supplementary figure E4d, e). Finally, to evaluate whether the bronchioid model accurately recapitulates small airways specifically at the transcriptional level, we used data from the HLCA and the CCF introduced therein [31]. A primary tissue reference across four distinct anatomical regions based on CCF was assembled, comprising cells from eight datasets marked broadly as airway epithelium in the HLCA (Methods, supplementary figure E5a–c). Bronchioid model cell states were compared to this primary tissue reference by performing a neighbourhood graph correlation-based similarity analysis (Methods) [30]. Overall, bronchioid cell states were more similar to cell states from the airways (CCF 0.32–0.5 and CCF 0.72–0.81) than to those from the nose (CCF 0) or parenchyma (CCF 0.97). Comparing the upper and lower airways, the similarity analysis results indicated that cell states from the distal airways (CCF 0.72–0.81) tended to more closely resemble bronchioid cell states (figure 4d, e). In summary, these data are consistent with the induction of distal airway fate in bronchioids, with identified cell states recapitulating distal airway epithelial cells at a global transcriptional level with high fidelity and differentiated cells localised to their corresponding *in vivo* positions.


#### **Functional analysis of ciliary beating in non-COPD- and COPD-derived bronchioids**

Using high-speed video microscopy [35], ciliary beating was observed in the bronchioid model (supplementary video E2). For bronchioids generated from four different patients, we determined the median CBF across different fields of acquisition (figure 5a, b). Overall, the median CBF values ranged




**FIGURE 3** Differentiation induction of primary bronchial epithelial cells into bronchioids. **a)** Expression of the genes *TP63*, *KRT5*, *SCGB1A1*, *FOXP1*, *DNAH5*, *AGR2* and *MUC5AC* in bronchioids over time and in cells dissociated from two-dimensional (2D) culture at day (D) 9 after air-liquid interface (ALI) introduction. The bronchioid and ALI culture samples were obtained from six and three different donors, respectively, and data are presented as mean±sd. Gene expression was normalised to that of the housekeeping genes *PPIA*, *RPL13* and *GusB* and expressed relative to that of basal epithelial cells in 2D submerged culture. **b)** Longitudinal and transverse sections and three-dimensional (3D) views of 3D reconstructions obtained from Z-stack confocal images of 11-day-old bronchioids stained for acetylated  $\alpha$ -tubulin (magenta), mucin-5AC (*MUC5AC*) (cyan) and nuclei (white). Arrows: ciliated cells; arrowheads: goblet cells. Scale bars: 50  $\mu$ m. **c)** Histograms of representative cell counts (y-axis) versus DAPI fluorescence (x-axis) of cells dissociated from bronchioids at the indicated time points. Dot plots represent cytokeratin-5/secretoglobulin family 1A member 1 (*SCGB1A1*)/*MUC5AC*/acetylated tubulin fluorescence (y-axis) versus forward side scatter (FSC) (x-axis). DAPI<sup>-</sup> cells, cytokeratin 5<sup>+</sup>, *SCGB1A1*<sup>+</sup>, *MUC5AC*<sup>+</sup> and acetylated tubulin<sup>+</sup> cells are shown in dark blue, green, orange, pink and purple, respectively. **d)** Percentages of DAPI<sup>-</sup>, cytokeratin 5<sup>+</sup>, *SCGB1A1*<sup>+</sup>, *MUC5AC*<sup>+</sup> and acetylated tubulin<sup>+</sup> cells over time. The samples are from four different non-COPD donors and data are presented as mean±sd.

from 6 Hz to 27 Hz (figure 5c), which is within the range of *in vivo* reference CBF values [36] and is also very similar to those found in bronchial epithelial strips [37], ALI cultures [38] and airway organoids [39]. Bronchioids derived from non-COPD patients were characterised by a physiological, biphasic spectrum of beating frequencies (figure 5c), as described for control ALI culture [40]. In contrast, COPD-derived bronchioids exhibited a loss of the biphasic spectrum and a shift towards lower frequencies (figure 5c).



**FIGURE 4** Single-cell transcriptome profiling in the bronchioid model. **a)** Uniform Manifold Approximation and Projection (UMAP) representation of single-cell RNA-sequencing (scRNA-seq) transcriptomic data showing the different cell types detected in 21-day-old bronchioids from two different non-COPD donors (Patients 1 and 2). **b)** Dot plot showing scaled mean expression (colour) and percentage of expressing cells (dot size) of selected marker genes in the indicated cell groups. **c)** Relative abundance of cell types identified in bronchioids from Patients 1 and 2. **d)** Bronchioid neighbourhoods, positioned with respect to the UMAP embedding of each index cell, are coloured by the maximum correlation value across primary lung tissue neighbourhoods from four distinct anatomical locations based on the common coordinate framework (CCF) established in the HLCA [31]. **e)** Box plot depicting neighbourhood similarities of bronchioid neighbourhoods with primary lung tissue neighbourhoods in the respective CCF category over major cell types identified in the bronchioid scRNA-seq data. The centre line indicates the median, the box limits indicate the upper and lower quantiles, and the whiskers indicate 1.5 $\times$  interquartile range. In **d** and **e**, the bronchioid neighbourhoods were constructed from cells integrated across the two samples.




**FIGURE 5** Fast Fourier transform (FFT) analysis of ciliary movement using high-speed video microscopy analysis. **a)** Schematic workflow for measuring ciliary beat frequency (CBF). Representative brightfield image corresponding to a part of a bronchioid at day 20. The coloured areas correspond to the regions of interest (ROIs) determined by the plugin Stardist 2D of the Fiji software on the image generated by a maximum intensity projection over time. Scale bar: 5  $\mu\text{m}$ . **b)** Representative measurements of the mean intensity in ROIs over time. The main frequency was determined using a FFT in each ROI. **c)** Violin plots showing the CBF of bronchioids derived from four different patients (non-COPD Patients 3 and 4, COPD Patients 5 and 6). For each patient, individual values represent median CBFs, determined in 9–10 fields.

#### *Rhinovirus infection and epithelial response in the bronchioid model*

We also used the model to test for rhinovirus infection, a major trigger of asthma and COPD exacerbation [41, 42]. To track viral infection, we injected a recombinant RV16 that accommodates GFP expression into the lumen of the bronchioid (figure 6a) [23]. Considering the calculated volume of the injection, estimated between 1  $\mu\text{L}$  and 3  $\mu\text{L}$  for a 5 cm-long bronchioid containing between 12 000 and 40 000 cells, with measured lumen diameters of  $\sim 200 \mu\text{m}$ , the MOI was  $\sim 0.5$  and 1.5. 48 h post-infection, 95% and 81% of the cells were GFP<sup>+</sup> in bronchioids generated from Patients 7 and 8, respectively (figure 6b, c), suggesting infection and viral RNA replication in the vast majority of cells, in agreement with the calculated MOI. The infection was less efficient (45% of GFP<sup>+</sup> cells) in bronchioids generated from Patient 9 (figure 6b, c). Next, we examined the effects of RV16 on cytokine secretion, including type I (IFN- $\beta$ ) and type III (IFN- $\lambda 1/3$ ) interferons and the chemokine CXCL8. RV16-GFP infection increased the levels of secreted IFN- $\beta$ , IFN- $\lambda 1/3$  and CXCL8 in comparison with the noninfected bronchioid condition for Patients 7 and 8 (figure 6d). No induction of interferon production or a modest increase in the CXCL8 level was observed in the bronchioids generated from Patient 9, which is in agreement with the decreased infection efficiency (figure 6d).

#### *Construction of an air-conducting bronchioid model*

To introduce an ALI, a 30 G needle was inserted at day 3 in the lumen of the bronchioid and connected to a dedicated perfusion system (figure 7a). We injected air, as shown by a change in refringence (figure 7a and supplementary video E3), and we maintained perfusion for 4 h by adjusting the flow rate to match the circulating flow in the distal bronchi with an internal diameter of 400  $\mu\text{m}$ , *i.e.* 0.2  $\text{mL}\cdot\text{min}^{-1}$ . Calcein staining indicated that the cells remained viable after 4 h of air perfusion (figure 7b). Air exposure resulted in the



**FIGURE 6** Rhinovirus infection in the bronchioid model. **a)** Experimental design for testing rhinovirus type 16 (RV16)-green fluorescent protein (GFP) infection. **b)** Histograms showing representative cell counts (y-axis) versus GFP fluorescence (x-axis) under different conditions at 48 h post-infection (p.i.). The percentages indicate the number of GFP<sup>+</sup> cells. **c)** Percentages of GFP<sup>+</sup> cells 48 h p.i. in bronchioids from three different donors (Patients 7, 8 and 9) under non-infected and infected (RV16-GFP) conditions. **d)** Interferon β (IFN-β), interferon λ1/3 (IFN-λ1/3) and C-X-C motif chemokine ligand 8 (CXCL8) concentrations in the medium from bronchioid cultures under different conditions. MOI: multiplicity of infection.

systematic upregulation of *SCGB1A1* in all the bronchioids perfused for 4 h (figure 7c). The expression of other genes tested showed either no variation (*TP63*, *KRT5*, *FOXJ1*, *AGR2*) or changes depending on the experiment (*DNAH5*, *MUC5AC*). Although a longer perfusion time may be required to observe more robust effects, this indicates the potential of the ALI to affect differentiation in a bronchioid model.


## Discussion

Taken together, our findings indicate that our bronchioid model offers several key advantages compared with current distal bronchial culture systems. In particular, in comparison with those of the classical 2D ALI model, the main advantages of our tubular system are the third dimension and the relevant geometry and stiffness, preventing the appearance of a nonphysiological population by epithelial–mesenchymal transition [43]. Compared with airway organoids, the bronchioid model also offers tubular geometry, with lumen access for air exposure and viral infection while retaining major characteristics of the airway epithelium. This system is also compatible with multiple biological analyses, such as immunohistochemistry, flow cytometry, transcriptomics and immunoblotting. We expect this model to be instrumental in uncovering cellular mechanisms leading to airflow obstruction and for implementing efficient drug testing assays.

ROCK pathway inhibition is considered important for lung organoid generation [44] because of its anti-apoptotic and proliferative effects [45]. We showed here that downregulation of MLC activity through the ROCK inhibitor Y-27632 was also required to facilitate the generation of an epithelial tubular structure that did not collapse. Importantly, the alteration of ROCK activity did not prevent cell–cell adhesion or epithelial differentiation, demonstrating the key role of 3D geometry and substrate stiffness.

The incorporation of primary BECs into 3D bioengineered structures is challenging, particularly due to the weak attachment of these cells to artificial substrates. The bronchioid collapse observed in the absence of ROCK inhibition may also result from insufficient adhesion to the inert alginate walls. Interestingly, tube collapse has also been observed during early lung development [46]. Thus, it is likely that there is further room for improvement in bronchioid development by favouring epithelial cell adhesion to the scaffold [7, 47] or by modulating luminal pressure [46].

Using flow cytometry, we demonstrated the progressive differentiation of basal cells into club, goblet and ciliated cells. Although we cannot rule out that differentiation may still be ongoing, the bronchioid contained a subset of differentiated cells at day 21. Together with the evidence of ciliary function and



**FIGURE 7** Establishment of an air-liquid interface in the bronchioid model. **a)** Setup for air perfusion. Created with BioRender.com. **b)** Upper panel: brightfield images of bronchioids before and during air perfusion. Lower panel: brightfield and fluorescence images of bronchioids after 4 h of perfusion and calcein staining. Scale bars: 200  $\mu\text{m}$ . **c)** Comparison of gene expression (*TP63*, *KRT5*, *SCGB1A1*, *FOXJ1*, *DNAH5*, *AGR2*, *MUC5AC*) in bronchioid tissue from four different non-COPD donors after 4 h of perfusion. Data are presented as mean  $\pm$  sd. Gene expression was normalised to that of the housekeeping genes *PPIA*, *RPL13* and *GusB* and expressed relative to that of bronchioids before perfusion (initial time).

mucus production, these findings indicate that the bronchioid model very likely displays fundamental mucociliary clearance properties.

At day 21, the cellular composition of the bronchioid was similar to that of airway organoids [11], with the percentage of goblet cells even slightly decreased compared to that of lung organoids. The limited set of markers used by flow cytometry did not allow us to identify all known cell types, with a substantial proportion of  $\sim 55\%$  of unidentified cells at day 21. These cells likely include a majority of intermediate secretory cells, in agreement with the findings of another flow cytometry study [48]. scRNA-seq analysis confirmed the identity of the major bronchial epithelial cell types in proportions intermediate between those of proximal and distal airways [34], together with a high level of similarity between the bronchioid and distal airway cell types at the transcriptional level. Thus, the dimensions and geometry of the bronchioid model, which is close to a 17th generation bronchiole, as well as its general composition, make it a relevant model of the distal airway. However, the cellular composition is not strictly similar to that of distal airways, with the absence of *SCGB3A2*<sup>+</sup> *SFTPB*<sup>+</sup> terminal airway-enriched secretory cells, a cell population that is specific to distal airways [33, 34]. This is a limitation of the current bronchioid model, which can be attributed to the proximal basal cells used in this study [33, 34] and/or to the absence of air exposure for this experiment. Indeed, our perfusion experiments indicated that the introduction of ALI for 4 h induced the upregulation of *SCGB1A1* expression (figure 6c). Although requiring further study, these effects are consistent with a shift towards a distal phenotype [49] and suggest the potential of the ALI bronchioid model to fully model distal airways.

We also demonstrated that bronchioids made from cells of COPD patients might recapitulate important pathological features of COPD. First, COPD bronchioids exhibited a mucous phenotype with increased numbers of goblet cells and reduced numbers of ciliated cells. These findings are in line with those

obtained in ALI cultures [40, 50] and organoid models [39] and suggest an altered differentiation trajectory in COPD bronchioids. Second, ciliary beating seems altered in COPD bronchioids, as previously shown in nasal cilia samples [51, 52] and airway organoids [39] derived from cells of COPD patients, and the loss of the biphasic distribution in ALI cultures from COPD patients [40]. Although the low number of patient replicates does not allow an accurate statistical analysis, this finding suggests the potential of using bronchioids to model respiratory diseases.

While lung organoids have been used to study infection by viruses such as respiratory syncytial virus [11], enterovirus [53], influenza [12, 54] and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [39, 55–57], infection usually requires organoid reorientation to achieve apical-out polarity [57, 58]. Polarity reversal by suspension culture requires extracellular matrix removal, resulting in the loss of the 3D-relevant environment and possibly affecting mechanotransduction pathways. In addition, this step takes at least 1–2 days and does not work 100% of the time. More importantly, this procedure affects cell viability in differentiated organoids, restricting its use in undifferentiated organoids. Using the bronchioid model, we demonstrated efficient rhinoviral infection through intraluminal virus injection, as well as an epithelial response. In contrast to microinjection into the centre of spherical organoids [59] or organoid mechanical disruption to expose the apical surface [60], our method does not affect the organoid wall because of the easy access to the lumen in the bronchioid model. This procedure is compatible with many types of downstream analyses, including flow cytometry and biochemical techniques. Whereas rhinovirus infection at a high dose has been previously reported to peak after 24 h in 2D ALI culture [61, 62], the high percentage of infected cells at 48 h post-infection in our study could be explained by possible re-infection, because the tube is not washed after infection. Notably, the concentration of IFN- $\lambda$ 1/3 in the medium appears lower than that measured in 2D ALI culture following rhinovirus infection [61], which could be explained by the fact that the volume of medium is much greater relative to the number of cells in our settings. Overall, our results demonstrate the value of bronchioid technology for studying infectious diseases and host–pathogen interactions.

In conclusion, we have generated a new workflow that allows the efficient generation of tubular structures that model distal airways and are built with epithelial cells derived from clinical samples. These bronchioids are susceptible to perfusion with liquid and, more importantly, with air to establish an ALI. Because metres of tubes are generated per condition and the duration of the assay is relatively short, high-throughput methods, particularly for drug screening and testing, can be applied in the context of respiratory disease modelling.

The widespread use of these tubular models in the field of lung science requires access to dedicated technology. Notably, alginate tubes compatible with the dimensions of distal airways have been generated by different groups [18–20] and only require relatively simple co-extrusion setups, as detailed in [63]. These setups are simple in comparison to those of bioprinters or to the equipment necessary to fabricate homemade lung-on-chip systems. In addition, there are simpler methods to generate alginate tubes with larger dimensions (typically of proximal airways) [64] that are accessible with classical equipment and expertise from a biology laboratory. Thus, the adaptability and expansibility of tubular lung organoids combined with the incorporation of patient cells, together with intraluminal exposure to pathogens and particles, hold tremendous potential for the replication of specific lung pathologies. Complexifying the model with nonepithelial cells will enable us to better understand the composition and function of distal airways. Ultimately, in-depth analyses, such as single-cell transcriptomics of patient-derived bronchioids, should provide invaluable insights into disease mechanisms and facilitate the screening of potential therapeutics.

**Acknowledgements:** We thank the study participants and the staff of the Thoracic Surgery, Respiratory, Lung Function Testing departments from the University Hospital of Bordeaux (Bordeaux, France); Isabelle Goasdoue, Isabelle Bernis, Natacha Robert, Virginie Niel and Marine Servat from the Clinical Investigation Center (Bordeaux, France) for technical assistance; Atika Zouine, Vincent Pitard, Laetitia Andrique, Vanessa Bergeron and Xavier Gauthereau for technical assistance at the VoxCell, FACSility and OneCell Facilities (CNRS UMS 3427, INSERM US 005, Univ. Bordeaux, F-33000 Bordeaux, France); and Christel Poujol, Magali Mondin, Sébastien Marais and Fabrice Cordelières for help with imaging and image analysis at the Bordeaux Imaging Centre (BIC; Bordeaux, France). Microscopy was performed at the BIC, a service unit of the CNRS-INSERM, and Bordeaux University, a member of the National BioImaging Infrastructure of France supported by the French National Research Agency (ANR-10-INBS-04). A-E. Saliba and A.M. Leipold thank Deutsche Forschungsgemeinschaft DFG SFB 1583 (project number 492620490; Z2 project), and A-E. Saliba thanks DFG GRK2157 for funding. A-E. Saliba, A.M. Leipold and T. Krammer thank CoreUnitSysmed for providing technical support for sequencing.

Data availability: scRNA-seq data generated in the current study are available on Zenodo under 10.5281/zenodo.10834205. The R code used for scRNA-seq data analysis has been deposited on GitHub: [https://github.com/saliba-lab/Bronchioid\\_scRNAseq](https://github.com/saliba-lab/Bronchioid_scRNAseq)

Ethics statement: Macroscopically normal lung resection material for the purification of basal epithelial cells was obtained from a cohort of patients requiring thoracic lobectomy surgery for nodule or cancer (pN0) (*i.e.* TUBE, sponsored by the University Hospital of Bordeaux, which includes its own local ethics committee, CHUBX 2020/54)). According to French law and the MR004 regulation, patients received an information form, allowing them to refuse the use of their surgical samples for research. The research was conducted according to the principles of the World Medical Association Declaration of Helsinki.

Author contributions: Conception and design, P. Nassoy, G. Recher and I. Dupin; data acquisition, E. Maurat, K. Raasch, V. Bergeron, L. Andrique, A.M. Leipold, T. Krammer, A-E. Saliba and G. Recher; data analysis, E. Maurat, K. Raasch, A.M. Leipold, A-E. Saliba and I. Dupin; data interpretation, E. Maurat, K. Raasch, A.M. Leipold, P. Henrot, M. Zysman, R. Prevel, T. Trian, L. Andrique, P. Berger, P. Nassoy, A-E. Saliba, G. Recher and I. Dupin; resources, P. Henrot, T. Trian, M. Thumerel, M. Zysman and P. Berger; drafting the manuscript, E. Maurat, K. Raasch and I. Dupin; revision and approval of the final version, all authors.

Conflict of interest: I. Dupin and P. Berger have two patents (EP number 3050574 and EP number 20173595). I. Dupin, P. Henrot and M. Zysman report grants from the Fondation Bordeaux Université. M. Zysman reports personal fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Novartis, Chiesi and GlaxoSmithKline, and non-financial support from Lilly. P. Berger reports grants and personal fees from Novartis; personal fees and non-financial support from Chiesi, Boehringer Ingelheim, AstraZeneca and Sanofi; and personal fees from Menarini and TEVA, outside the submitted work. All other authors declare that they have no competing interests.

Support statement: The project was funded by the Agence Nationale de la Recherche (ANR-21-CE18-0001-01) (I. Dupin), the Region Nouvelle Aquitaine (I. Dupin) (AAPR2022A- 2021-16982910 and AAPR2022I-2021-16983510), the Department Sciences et Technologies of Bordeaux University (I. Dupin) and the Institut Universitaire de France (IUF) (I. Dupin). Funding information for this article has been deposited with the Crossref Funder Registry.

## References

- 1 Ghorani V, Boskabady MH, Khazdair MR, *et al.* Experimental animal models for COPD: a methodological review. *Tob Induc Dis* 2017; 15: 25.
- 2 Nizamoglu M, Joglekar MM, Almeida CR, *et al.* Innovative three-dimensional models for understanding mechanisms underlying lung diseases: powerful tools for translational research. *Eur Respir Rev* 2023; 32: 230042.
- 3 Jorissen M, Van der Schueren B, Van den Berghe H, *et al.* Contribution of *in vitro* culture methods for respiratory epithelial cells to the study of the physiology of the respiratory tract. *Eur Respir J* 1991; 4: 210–217.
- 4 Adler KB, Cheng PW, Kim KC. Characterization of guinea pig tracheal epithelial cells maintained in biphasic organotypic culture: cellular composition and biochemical analysis of released glycoconjugates. *Am J Respir Cell Mol Biol* 1990; 2: 145–154.
- 5 Dabaghi M, Carpio MB, Moran-Mirabal JM, *et al.* 3D (bio)printing of lungs: past, present, and future. *Eur Respir J* 2023; 61: 2200417.
- 6 De Santis MM, Bölükbas DA, Lindstedt S, *et al.* How to build a lung: latest advances and emerging themes in lung bioengineering. *Eur Respir J* 2018; 52: 1601355.
- 7 De Santis MM, Alsafadi HN, Tas S, *et al.* Extracellular-matrix-reinforced bioinks for 3D bioprinting human tissue. *Adv Mater* 2021; 33: e2005476.
- 8 Huh D, Matthews BD, Mammoto A, *et al.* Reconstituting organ-level lung functions on a chip. *Science* 2010; 328: 1662–1668.
- 9 Benam KH, Villenave R, Lucchesi C, *et al.* Small airway-on-a-chip enables analysis of human lung inflammation and drug responses *in vitro*. *Nat Methods* 2016; 13: 151–157.
- 10 Benali R, Tournier JM, Chevillard M, *et al.* Tubule formation by human surface respiratory epithelial cells cultured in a three-dimensional collagen lattice. *Am J Physiol* 1993; 264: L183–L192.
- 11 Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, *et al.* Long-term expanding human airway organoids for disease modeling. *EMBO J* 2019; 38: e100300.
- 12 Zhou J, Li C, Sachs N, *et al.* Differentiated human airway organoids to assess infectivity of emerging influenza virus. *Proc Natl Acad Sci USA* 2018; 115: 6822–6827.
- 13 Lamers MM, van der Vaart J, Knoops K, *et al.* An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. *EMBO J* 2020; 40: e105912.
- 14 Hiemstra PS, Tetley TD, Janes SM. Airway and alveolar epithelial cells in culture. *Eur Respir J* 2019; 54: 1900742.
- 15 Boecking CA, Walentek P, Zlock LT, *et al.* A simple method to generate human airway epithelial organoids with externally orientated apical membranes. *Am J Physiol Lung Cell Mol Physiol* 2022; 322: L420–L437.

- 16 Stroulios G, Brown T, Moreni G, *et al.* Apical-out airway organoids as a platform for studying viral infections and screening for antiviral drugs. *Sci Rep* 2022; 12: 7673.
- 17 Tan Q, Choi KM, Sicard D, *et al.* Human airway organoid engineering as a step toward lung regeneration and disease modeling. *Biomaterials* 2017; 113: 118–132.
- 18 Onoe H, Okitsu T, Itou A, *et al.* Metre-long cell-laden microfibrils exhibit tissue morphologies and functions. *Nat Mater* 2013; 12: 584–590.
- 19 Andrique L, Recher G, Alessandri K, *et al.* A model of guided cell self-organization for rapid and spontaneous formation of functional vessels. *Sci Adv* 2019; 5: eaau6562.
- 20 Maechler FA, Allier C, Roux A, *et al.* Curvature-dependent constraints drive remodeling of epithelia. *J Cell Sci* 2019; 132: jcs222372.
- 21 Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2023. Global Strategy for the Diagnosis, Prevention and Management of COPD. Available from: <https://goldcopd.org/>
- 22 Trian T, Allard B, Dupin I, *et al.* House dust mites induce proliferation of severe asthmatic smooth muscle cells via an epithelium-dependent pathway. *Am J Respir Crit Care Med* 2015; 191: 538–546.
- 23 Olszewski D, Georgi F, Murer L, *et al.* High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections. *Sci Data* 2022; 9: 610.
- 24 Lee W-M, Wang W, Bochkov YA, *et al.* Reverse genetics system for studying human rhinovirus infections. *Methods Mol Biol* 2015; 1221: 149–170.
- 25 Maestre-Batlle D, Pena OM, Hirota JA, *et al.* Novel flow cytometry approach to identify bronchial epithelial cells from healthy human airways. *Sci Rep* 2017; 7: 42214.
- 26 Dekkers JF, Alieva M, Wellens LM, *et al.* High-resolution 3D imaging of fixed and cleared organoids. *Nat Protoc* 2019; 14: 1756–1771.
- 27 Hao Y, Stuart T, Kowalski MH, *et al.* Dictionary learning for integrative, multimodal and scalable single-cell analysis. *Nat Biotechnol* 2024; 42: 293–304.
- 28 Domínguez Conde C, Xu C, Jarvis LB, *et al.* Cross-tissue immune cell analysis reveals tissue-specific features in humans. *Science* 2022; 376: eabl5197.
- 29 The Integrated Human Lung Cell Atlas. 2020. Available from: <https://cellxgene.cziscience.com/collections/6f6d381a-7701-4781-935c-db10d30de293>
- 30 Ton M-LN, Keitley D, Theeuwes B, *et al.* An atlas of rabbit development as a model for single-cell comparative genomics. *Nat Cell Biol* 2023; 25: 1061–1072.
- 31 Sikkema L, Ramírez-Suástegui C, Strobl DC, *et al.* An integrated cell atlas of the lung in health and disease. *Nat Med* 2023; 29: 1563–1577.
- 32 Dann E, Henderson NC, Teichmann SA, *et al.* Differential abundance testing on single-cell data using k-nearest neighbor graphs. *Nat Biotechnol* 2022; 40: 245–253.
- 33 Kadur Lakshminarasimha Murthy P, Sontake V, Tata A, *et al.* Human distal lung maps and lineage hierarchies reveal a bipotent progenitor. *Nature* 2022; 604: 111–119.
- 34 Rustam S, Hu Y, Mahjour SB, *et al.* A unique cellular organization of human distal airways and its disarray in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2023; 207: 1171–1182.
- 35 Jackson CL, Bottier M. Methods for the assessment of human airway ciliary function. *Eur Respir J* 2022; 60: 2102300.
- 36 Low PM, Luk CK, Dulfano MJ, *et al.* Ciliary beat frequency of human respiratory tract by different sampling techniques. *Am Rev Respir Dis* 1984; 130: 497–498.
- 37 Thomas B, Rutman A, Hirst RA, *et al.* Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. *J Allergy Clin Immunol* 2010; 126: 722–729.
- 38 Hirst RA, Jackson CL, Coles JL, *et al.* Culture of primary ciliary dyskinesia epithelial cells at air–liquid interface can alter ciliary phenotype but remains a robust and informative diagnostic aid. *PLoS One* 2014; 9: e89675.
- 39 Chan LLY, Anderson DE, Cheng HS, *et al.* The establishment of COPD organoids to study host–pathogen interaction reveals enhanced viral fitness of SARS-CoV-2 in bronchi. *Nat Commun* 2022; 13: 7635.
- 40 Stoleriu MG, Ansari M, Strunz M, *et al.* COPD basal cells are primed towards secretory to multiciliated cell imbalance driving increased resilience to environmental stressors. *Thorax* 2024; 79: 524–537.
- 41 Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2004; 1: 115–120.
- 42 Message SD, Laza-Stanca V, Mallia P, *et al.* Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. *Proc Natl Acad Sci USA* 2008; 105: 13562–13567.
- 43 Greaney AM, Adams TS, Brickman Raredon MS, *et al.* Platform effects on regeneration by pulmonary basal cells as evaluated by single-cell RNA sequencing. *Cell Rep* 2020; 30: 4250–4265.
- 44 Kim J, Koo B-K, Knoblich JA. Human organoids: model systems for human biology and medicine. *Nat Rev Mol Cell Biol* 2020; 21: 571–584.
- 45 Watanabe K, Ueno M, Kamiya D, *et al.* A ROCK inhibitor permits survival of dissociated human embryonic stem cells. *Nat Biotechnol* 2007; 25: 681–686.

- 46 Conrad L, Runser SVM, Fernando Gómez H, *et al.* The biomechanical basis of biased epithelial tube elongation in lung and kidney development. *Development* 2021; 148: dev194209.
- 47 Hamilton NJI, Lee DDH, Gowers KHC, *et al.* Bioengineered airway epithelial grafts with mucociliary function based on collagen IV- and laminin-containing extracellular matrix scaffolds. *Eur Respir J* 2020; 55: 1901200.
- 48 Bonser LR, Koh KD, Johansson K, *et al.* Flow-cytometric analysis and purification of airway epithelial-cell subsets. *Am J Respir Cell Mol Biol* 2021; 64: 308–317.
- 49 Yang J, Zuo W-L, Fukui T, *et al.* Smoking-dependent distal-to-proximal repatterning of the adult human small airway epithelium. *Am J Respir Crit Care Med* 2017; 196: 340–352.
- 50 Gohy S, Carlier FM, Fregimilicka C, *et al.* Altered generation of ciliated cells in chronic obstructive pulmonary disease. *Sci Rep* 2019; 9: 17963.
- 51 Yaghi A, Zaman A, Cox G, *et al.* Ciliary beating is depressed in nasal cilia from chronic obstructive pulmonary disease subjects. *Respir Med* 2012; 106: 1139–1147.
- 52 Piatti G, Ambrosetti U, Santus P, *et al.* Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. *Pharmacol Res* 2005; 51: 165–168.
- 53 van der Sanden SMG, Sachs N, Koekkoek SM, *et al.* Enterovirus 71 infection of human airway organoids reveals VP1-145 as a viral infectivity determinant. *Emerg Microbes Infect* 2018; 7: 84.
- 54 Hui KPY, Ching RHH, Chan SKH, *et al.* Tropism, replication competence, and innate immune responses of influenza virus: an analysis of human airway organoids and *ex vivo* bronchus cultures. *Lancet Respir Med* 2018; 6: 846–854.
- 55 Han Y, Duan X, Yang L, *et al.* Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. *Nature* 2021; 589: 270–275.
- 56 Youk J, Kim T, Evans KV, *et al.* Three-dimensional human alveolar stem cell culture models reveal infection response to SARS-CoV-2. *Cell Stem Cell* 2020; 27: 905–919.
- 57 Salahudeen AA, Choi SS, Rustagi A, *et al.* Progenitor identification and SARS-CoV-2 infection in human distal lung organoids. *Nature* 2020; 588: 670–675.
- 58 Co JY, Margalef-Català M, Monack DM, *et al.* Controlling the polarity of human gastrointestinal organoids to investigate epithelial biology and infectious diseases. *Nat Protoc* 2021; 16: 5171–5192.
- 59 Iakobachvili N, Leon-Icaza SA, Knoops K, *et al.* Mycobacteria–host interactions in human bronchiolar airway organoids. *Mol Microbiol* 2022; 117: 682–692.
- 60 Lamers MM, Beumer J, van der Vaart J, *et al.* SARS-CoV-2 productively infects human gut enterocytes. *Science* 2020; 369: 50–54.
- 61 Veerati PC, Troy NM, Reid AT, *et al.* Airway epithelial cell immunity is delayed during rhinovirus infection in asthma and COPD. *Front Immunol* 2020; 11: 974.
- 62 Warner SM, Wiehler S, Michi AN, *et al.* Rhinovirus replication and innate immunity in highly differentiated human airway epithelial cells. *Respir Res* 2019; 20: 150.
- 63 Alessandri K, Sarangi BR, Gurchenkov VV, *et al.* Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression *in vitro*. *Proc Natl Acad Sci USA* 2013; 110: 14843–14848.
- 64 Da Silva IA, Gvazava N, Putra Wendi I, *et al.* Formalin-free fixation and xylene-free tissue processing preserves cell-hydrogel interactions for histological evaluation of 3D calcium alginate tissue engineered constructs. *Frontiers in Biomaterials Science* 2023; 2: 1155919.